Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)

32 Páginas.

Autores:: Bustos Sánchez, José Luis

Tipo de recurso:

Fecha de publicación:: 2017

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: spa

id	REPOUSABAN_826f13011174cdd6d7a3cfd8d7fd0f63
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/31146
network_acronym_str	REPOUSABAN
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
dc.title.es_CO.fl_str_mv	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
title	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
spellingShingle	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA) Enfermedad cerebrovascular Atención al enfermo Neurología Personal de salud
title_short	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
title_full	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
title_fullStr	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
title_full_unstemmed	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
title_sort	Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)
dc.creator.fl_str_mv	Bustos Sánchez, José Luis
dc.contributor.advisor.none.fl_str_mv	Sarmiento Medina, Pedro José
dc.contributor.author.none.fl_str_mv	Bustos Sánchez, José Luis
dc.subject.none.fl_str_mv	Enfermedad cerebrovascular Atención al enfermo Neurología Personal de salud
topic	Enfermedad cerebrovascular Atención al enfermo Neurología Personal de salud
description	32 Páginas.
publishDate	2017
dc.date.accessioned.none.fl_str_mv	2017-08-09T14:26:32Z
dc.date.available.none.fl_str_mv	2017-08-09T14:26:32Z
dc.date.created.none.fl_str_mv	2017
dc.date.issued.none.fl_str_mv	2017-08-09
dc.type.es_CO.fl_str_mv	bachelorThesis
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_7a1f
dc.type.local.none.fl_str_mv	Tesis de especialización
dc.type.hasVersion.none.fl_str_mv	publishedVersion
dc.identifier.citation.none.fl_str_mv	Charcot J-M. De la sclérose latérale amyotrophique. Prog Med. 1874;2:325¿7. Katz JS, Dimachkie MM, Barohn RJ. Amyotrophic lateral sclerosis: A historical perspective. Neurol Clin. 2015;33(4):727¿34. Bell C. The nervous system of the human body. London: Longman;1830. p. 132-6 (Special Edition, copyright Classics of Neurology and Neurosurgery Library, Birmingham Alabama 1985). Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5¿6):310¿23 Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745¿51. Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev Neurol (Paris). 2016;172(1):37¿45. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942¿55. Oliver D, Borasio, GD, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis¿: From Diagnosis to Bereavement. Second edition. New York: Oxford University Press; 2006. 352 p. Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12(2):181¿4. Mathis S, Couratier P, Julian A, Vallat J-M, Corcia P, Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev Neurother. 2017;17(3):263¿276. Zarranz J. Neurología. quinta edición. Madrid: Elsevier; 2013. 752 p. Brooks BR. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124 Suppl:96¿107. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293¿9. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503. Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009;10(1):53¿7. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?. Front Aging Neurosci. 2017;9:1¿11. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360¿75. Greenberg MK, Alter M, Calverley J, Miller RG, Franklin G, French J, et al. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet]. 1997;49(3):657¿9. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis¿: a randomised, double-blind, placebo-controlled trial. 2017; 16(7): 505-512. Hardiman O, van den Berg LH. Edaravone¿: a new treatment for ALS on the horizon¿?. Lancet Neurol. 2017;16(7):490¿1. Seitzer F, Kahrass H, Neitzke G, Strech D. The full spectrum of ethical issues in the care of patients with ALS: a systematic qualitative review. J Neurol. 2016;263(2):201- 9. Jha V, Martin DE, Bargman JM, Davies S, Feehally J, Finkelstein F, et al. Ethical issues in dialysis therapy. Lancet. 2017;389:1851¿6. Eisen A, Krieger C. Ethical considerations in the management of amyotrophic lateral sclerosis. Prog Neurobiol. 2013;110:45¿53. Orient-López F, Terré-Boliart R, Guevara-Espinosa D, Bernabeu-Guitart M. Tratamiento neurorrehabilitador de la esclerosis lateral amiotrófica. Rev Neurol. 2006;43(9):549¿55. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update¿: The care of the patient with amyotrophic lateral sclerosis¿: Multidisciplinary care , symptom management and cognitive/behavioral impairment (an evidence-based review)¿: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227¿33. Beauchamp T, Childress J. Principles of Bioedical Ethics. Five Editi. New York: Oxford University Press; 2001. Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99(3):792¿803. O¿Reilly ÉJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):205¿11. Soriani M-H, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173(5):288¿99. Stavroulakis T, Walsh T, Shaw PJ, McDermott CJ. Gastrostomy use in motor neurone disease (MND): A review, meta-analysis and survey of current practice. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):96¿104.
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/31146
dc.identifier.local.none.fl_str_mv	265444 TE09191
identifier_str_mv	Charcot J-M. De la sclérose latérale amyotrophique. Prog Med. 1874;2:325¿7. Katz JS, Dimachkie MM, Barohn RJ. Amyotrophic lateral sclerosis: A historical perspective. Neurol Clin. 2015;33(4):727¿34. Bell C. The nervous system of the human body. London: Longman;1830. p. 132-6 (Special Edition, copyright Classics of Neurology and Neurosurgery Library, Birmingham Alabama 1985). Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5¿6):310¿23 Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745¿51. Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev Neurol (Paris). 2016;172(1):37¿45. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942¿55. Oliver D, Borasio, GD, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis¿: From Diagnosis to Bereavement. Second edition. New York: Oxford University Press; 2006. 352 p. Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12(2):181¿4. Mathis S, Couratier P, Julian A, Vallat J-M, Corcia P, Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev Neurother. 2017;17(3):263¿276. Zarranz J. Neurología. quinta edición. Madrid: Elsevier; 2013. 752 p. Brooks BR. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124 Suppl:96¿107. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293¿9. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503. Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009;10(1):53¿7. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?. Front Aging Neurosci. 2017;9:1¿11. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360¿75. Greenberg MK, Alter M, Calverley J, Miller RG, Franklin G, French J, et al. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet]. 1997;49(3):657¿9. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis¿: a randomised, double-blind, placebo-controlled trial. 2017; 16(7): 505-512. Hardiman O, van den Berg LH. Edaravone¿: a new treatment for ALS on the horizon¿?. Lancet Neurol. 2017;16(7):490¿1. Seitzer F, Kahrass H, Neitzke G, Strech D. The full spectrum of ethical issues in the care of patients with ALS: a systematic qualitative review. J Neurol. 2016;263(2):201- 9. Jha V, Martin DE, Bargman JM, Davies S, Feehally J, Finkelstein F, et al. Ethical issues in dialysis therapy. Lancet. 2017;389:1851¿6. Eisen A, Krieger C. Ethical considerations in the management of amyotrophic lateral sclerosis. Prog Neurobiol. 2013;110:45¿53. Orient-López F, Terré-Boliart R, Guevara-Espinosa D, Bernabeu-Guitart M. Tratamiento neurorrehabilitador de la esclerosis lateral amiotrófica. Rev Neurol. 2006;43(9):549¿55. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update¿: The care of the patient with amyotrophic lateral sclerosis¿: Multidisciplinary care , symptom management and cognitive/behavioral impairment (an evidence-based review)¿: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227¿33. Beauchamp T, Childress J. Principles of Bioedical Ethics. Five Editi. New York: Oxford University Press; 2001. Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99(3):792¿803. O¿Reilly ÉJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):205¿11. Soriani M-H, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173(5):288¿99. Stavroulakis T, Walsh T, Shaw PJ, McDermott CJ. Gastrostomy use in motor neurone disease (MND): A review, meta-analysis and survey of current practice. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):96¿104. 265444 TE09191
url	http://hdl.handle.net/10818/31146
dc.language.iso.es_CO.fl_str_mv	spa
language	spa
dc.rights.*.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_16ec
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_16ec
dc.publisher.es_CO.fl_str_mv	Universidad de La Sabana
dc.publisher.program.none.fl_str_mv	Especialización en Bioética
dc.publisher.department.none.fl_str_mv	Facultad de Medicina
dc.source.none.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d580-52b7-e053-7e0910accd73/download https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d581-52b7-e053-7e0910accd73/download https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5cc-52b7-e053-7e0910accd73/download https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5c2-52b7-e053-7e0910accd73/download https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5c3-52b7-e053-7e0910accd73/download https://dspace-unisabana.metabuscador.org/bitstreams/4e363829-77d9-4908-8b8a-e684df95d881/download
bitstream.checksum.fl_str_mv	f52a2cfd4df262e08e9b300d62c85cab d6d5cd8291be938a265cf50d95244e94 ced2af8d3dd529549a015dbc0974be1e ab3bb0edcb174cc3a46482b3ac6fee14 7c9ab7f006165862d8ce9ac5eac01552 f7fefc8052d0d404475eeff2cf454ae6
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Intellectum Repositorio Universidad de La Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1841674700713885696
spelling	Sarmiento Medina, Pedro JoséBustos Sánchez, José LuisEspecialista en Bioética2017-08-09T14:26:32Z2017-08-09T14:26:32Z20172017-08-09Charcot J-M. De la sclérose latérale amyotrophique. Prog Med. 1874;2:325¿7.Katz JS, Dimachkie MM, Barohn RJ. Amyotrophic lateral sclerosis: A historical perspective. Neurol Clin. 2015;33(4):727¿34.Bell C. The nervous system of the human body. London: Longman;1830. p. 132-6 (Special Edition, copyright Classics of Neurology and Neurosurgery Library, Birmingham Alabama 1985).Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5¿6):310¿23Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16(6):745¿51.Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. Rev Neurol (Paris). 2016;172(1):37¿45.Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942¿55.Oliver D, Borasio, GD, Walsh D. Palliative Care in Amyotrophic Lateral Sclerosis¿: From Diagnosis to Bereavement. Second edition. New York: Oxford University Press; 2006. 352 p.Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12(2):181¿4.Mathis S, Couratier P, Julian A, Vallat J-M, Corcia P, Le Masson G. Management and therapeutic perspectives in amyotrophic lateral sclerosis. Expert Rev Neurother. 2017;17(3):263¿276.Zarranz J. Neurología. quinta edición. Madrid: Elsevier; 2013. 752 p.Brooks BR. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci. 1994;124 Suppl:96¿107.Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Mot Neuron Disord. 2000;1(5):293¿9.de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119(3):497-503.Carvalho MD, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009;10(1):53¿7.Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?. Front Aging Neurosci. 2017;9:1¿11.Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360¿75.Greenberg MK, Alter M, Calverley J, Miller RG, Franklin G, French J, et al. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology [Internet]. 1997;49(3):657¿9.Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis¿: a randomised, double-blind, placebo-controlled trial. 2017; 16(7): 505-512.Hardiman O, van den Berg LH. Edaravone¿: a new treatment for ALS on the horizon¿?. Lancet Neurol. 2017;16(7):490¿1.Seitzer F, Kahrass H, Neitzke G, Strech D. The full spectrum of ethical issues in the care of patients with ALS: a systematic qualitative review. J Neurol. 2016;263(2):201- 9.Jha V, Martin DE, Bargman JM, Davies S, Feehally J, Finkelstein F, et al. Ethical issues in dialysis therapy. Lancet. 2017;389:1851¿6.Eisen A, Krieger C. Ethical considerations in the management of amyotrophic lateral sclerosis. Prog Neurobiol. 2013;110:45¿53.Orient-López F, Terré-Boliart R, Guevara-Espinosa D, Bernabeu-Guitart M. Tratamiento neurorrehabilitador de la esclerosis lateral amiotrófica. Rev Neurol. 2006;43(9):549¿55.Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice Parameter update¿: The care of the patient with amyotrophic lateral sclerosis¿: Multidisciplinary care , symptom management and cognitive/behavioral impairment (an evidence-based review)¿: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227¿33.Beauchamp T, Childress J. Principles of Bioedical Ethics. Five Editi. New York: Oxford University Press; 2001.Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, et al. Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis. Am J Clin Nutr. 2014;99(3):792¿803.O¿Reilly ÉJ, Wang H, Weisskopf MG, Fitzgerald KC, Falcone G, McCullough ML, et al. Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):205¿11.Soriani M-H, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173(5):288¿99.Stavroulakis T, Walsh T, Shaw PJ, McDermott CJ. Gastrostomy use in motor neurone disease (MND): A review, meta-analysis and survey of current practice. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(2):96¿104.http://hdl.handle.net/10818/31146265444TE0919132 Páginas.La ELA es una enfermedad de baja prevalencia si la comparamos con patologías neurológicas habituales como la cefalea o la enfermedad cerebrovascular, pero la afectación funcional que llega a generar es devastadora en un mediano tiempo, por lo infrecuente de esta entidad nosológica es que se retrasa su diagnóstico y desde ese momento empieza el sufrimiento del paciente, pero considero que el equipo médico sufre también al no tener habitualmente las herramientas necesarias para las intervenciones que este tipo de pacientes amerita junto a un sistema de salud que tampoco está preparado y que fácilmente pueden convertirse en agravantes de ese sufrimiento del enfermo. Esta monografía busca desde una perspectiva de bioética personalista ilustrar al personal de salud en especial neurólogos sobre el conocimiento actual y las oportunidades de intervención para con estos pacientes a fin que les ofrezcamos verdaderas soluciones a sus quejas y seamos buenos concejeros en los conflictos que esta patología genera.spaUniversidad de La SabanaEspecialización en BioéticaFacultad de MedicinaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_16ecUniversidad de La SabanaIntellectum Repositorio Universidad de La SabanaEnfermedad cerebrovascularAtención al enfermoNeurologíaPersonal de saludConsideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)bachelorThesisTesis de especializaciónpublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_7a1fPublicationLICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d580-52b7-e053-7e0910accd73/downloadf52a2cfd4df262e08e9b300d62c85cabMD53falseAdministratorREADAnonymousREADJosé Luis Bustos Sánchez (Carta).pdfJosé Luis Bustos Sánchez (Carta).pdfapplication/pdf345005https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d581-52b7-e053-7e0910accd73/downloadd6d5cd8291be938a265cf50d95244e94MD54falseTEXTJosé Luis Bustos Sánchez (Tesis).pdf.txtJosé Luis Bustos Sánchez (Tesis).pdf.txtExtracted Texttext/plain56725https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5cc-52b7-e053-7e0910accd73/downloadced2af8d3dd529549a015dbc0974be1eMD55falseORIGINALJosé Luis Bustos Sánchez (Tesis).pdfJosé Luis Bustos Sánchez (Tesis).pdfVer documento en PDFapplication/pdf531637https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5c2-52b7-e053-7e0910accd73/downloadab3bb0edcb174cc3a46482b3ac6fee14MD51trueCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81223https://dspace-unisabana.metabuscador.org/bitstreams/7bdf9f62-d5c3-52b7-e053-7e0910accd73/download7c9ab7f006165862d8ce9ac5eac01552MD52falseAdministratorREADAnonymousREADTHUMBNAILJosé Luis Bustos Sánchez (Tesis).pdf.jpgJosé Luis Bustos Sánchez (Tesis).pdf.jpgGenerated Thumbnailimage/jpeg5176https://dspace-unisabana.metabuscador.org/bitstreams/4e363829-77d9-4908-8b8a-e684df95d881/downloadf7fefc8052d0d404475eeff2cf454ae6MD56false10818/31146oai:dspace-unisabana.metabuscador.org:10818/311462025-08-09 04:49:33.228http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internationalrestrictedhttps://dspace-unisabana.metabuscador.orgIntellectum Repositorio Universidad de La Sabanacontactointellectum@unisabana.edu.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

Consideraciones éticas sobre el compromiso respiratorio de los pacientes con esclerosis lateral amiotrófica (ELA)

Publicaciones similares